– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
Clinical-stage biotechnology company Immunic, Inc. (NASDAQ:IMUX) is focused on developing an orally administered, small-molecule therapy for treating multiple sclerosis (MS). In our last article, we ...
As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...
Hosted on MSN
Multiple sclerosis: three trials to watch
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to discuss trials in the indication that could alter the current ...
Roche is eyeing regulatory approval for its oral multiple sclerosis (MS) hopeful, fenebrutinib, after the drug met its primary endpoints in two Phase III trials. During the FENhance 2 (NCT04586023) ...
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback